Amgen Expects Quick, Broad Adoption Of Tezspire In Severe Asthma
Executive Summary
Company says new asthma drug partnered with AstraZeneca will offer a new therapy option for severe patients with low eosinophil counts. The firms will provide launch plans in January.
You may also be interested in...
What Sanofi Early Research Chief Scientist Frank Nestle Is Most Excited About
Sanofi's Nestle talked to In Vivo about the company's early pipeline, the emerging technologies he thinks are most promising, and tapping external innovation.
Upstream Launches With $200m To Buy, Develop Drugs For Immune-Mediated Diseases
Upstream Bio acquired Phase Ib-ready UPB-101 from Astellas, and its experienced team plans to buy additional drug candidates for the treatment of allergic and inflammatory diseases.
Amgen Rebuilt R&D Platform To Focus On Speed And Access
The company explained during its recent business review how its R&D organization is pursuing the strategic objectives of improving success rates, reducing cycle times and enabling access to novel drugs.